ABBV Stock Analysis: Buy, Sell, or Hold?
ABBV - ABBVIE INC.
$261.07
10.01 (3.99%)
▲
5d:
+7.37%
30d:
+21.2%
90d:
+21.44%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 30, 2026
26d
Smart Money Distribution
None View Scanner →
Strength: 8.0/10
Get Alerted When ABBV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ABBV this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ABBV is 7.5% above its trading range ($242.94). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ABBV is 7.5% above its trading range ($242.94). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$355.98
Based on 9.1% avg growth
INTRINSIC VALUE TODAY
$221.03
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABBV is currently trading at $261.07, which is considered extended relative to its 30-day fair value range of $215.17 to $242.94. From a valuation perspective, the stock is trading at a premium (Forward PE: 16.1) compared to its historical average (14.2). At these levels, the market is pricing in 4.2% annual earnings growth.
Technical Outlook: Technically, ABBV is in a strong uptrend. The price is approaching resistance at $261.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: ABBV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABBV is in a strong uptrend. The price is approaching resistance at $261.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: ABBV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$215.17 -
$242.94
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
60.5%
Protect Your Profits
ABBV is technically overbought (RSI 77). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+7.5% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- NEUTRAL: Near Wall St target ($256.14)
- BULLISH: Expecting earnings turnaround to 4.2% growth with 12.4% revenue growth
- CAUTION: Extended 7.5% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$215.17 -
$242.94
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$215.37
Resistance Level
$261.64
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.05
Wall Street Target
$256.14
(-1.9%)
Revenue Growth (YoY)
12.4%
Earnings Growth (YoY)
-46.2%
Profit Margin
5.8%
Valuation Premium vs History
+4.2% premium
PE vs Historical
16.1 vs 14.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.2%
(market-implied from PE analysis)
1-Year Target
$272.03
(+4%)
2-Year Target
$283.46
(+9%)
3-Year Target
$295.37
(+13%)
3-Yr Target (if PE normalizes)
(PE: 16→14)
PE COMPRESSION
$261.27
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 14.2%)
$526.89
(+102%)
Base:
(SPY PE: 16.1, Growth: 14.2%)
$388.34
(+49%)
Bear:
(PE: 13.6, Growth: 14.2%)
$330.09
(+26%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Forward PE: 17.64 | Forward EPS (Implied): $14.80
Bull Case
$315.24
(+21%)
Analyst growth 15.0%, PE expands to 18.5
Base Case
$261.07
(0%)
Market implied 0.0%, PE stable at 17.6
Bear Case
$199.72
(-24%)
Severe decline -15.0%, PE contracts to 15.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 4:53 PM ET
Data refreshes hourly during market hours. Next update: 5:53 PM
Data refreshes hourly during market hours. Next update: 5:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABBV showing a specific setup today?
Insider Activity (6 Months)
2
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-03-30
David Ryan Purdue
SELL
5230 shares
2026-03-04
Perry C Siatis
SELL
22381 shares
2026-02-25
Featured in Portfolios
ABBV is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1223 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 67 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 69 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 67 BUY |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$130 | 62 BUY |
Advanced ABBV Option Strategies
Professional options setups generated by AI based on today's ABBV price and gamma walls.
